Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cetuximab-induced acne.

Emmanuel Molinari1, Julie De Quatrebarbes, Thierry André

  • 1Service de Dermatologie, Hôpital Tenon, Paris, France. emolinari@noos.fr

Dermatology (Basel, Switzerland)
|November 16, 2005
PubMed
Summary

Cetuximab, an anti-cancer drug, frequently causes a unique type of acne. This drug-induced acne, though distinct from typical acne, effectively responds to standard anti-acne treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral serotonin regulates epidermal differentiation and dermal homeostasis.

The Journal of investigative dermatology·2026
Same author

Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.

Neurosurgery·2026
Same author

International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes.

Journal of the American Academy of Dermatology·2025
Same author

Genetic landscape of non-UV-induced cutaneous squamous cell carcinomas.

The Journal of pathology·2025
Same author

Risk factors for recurrence or relapse after a first episode of adult IgA vasculitis: A multicenter retrospective study.

Journal of the American Academy of Dermatology·2025
Same author

Genomic and clinical characterization of anogenital basal cell carcinoma: A retrospective and prospective cohort study.

Journal of the American Academy of Dermatology·2025

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Cetuximab is an antineoplastic agent targeting epidermal growth factor receptor (EGFR).
  • EGFR inhibitors, including cetuximab, are known to cause acneiform eruptions.
  • The characteristics and treatment of cetuximab-induced acne require further investigation.

Purpose of the Study:

  • To characterize the features of acneiform eruptions induced by cetuximab.
  • To assess the efficacy of conventional anti-acne treatments for cetuximab-induced acne.

Main Methods:

  • Prospective evaluation of patients treated with cetuximab.
  • Documentation of acne presence, severity, and treatment response.
  • Analysis of acne characteristics, including site involvement and presence of comedones.

Main Results:

  • 85% of patients developed acneiform eruptions within 10 days of cetuximab treatment.
  • Acne was severe in 31% of affected patients.
  • Comedones were absent, and eruptions occurred at non-classical sites in some patients; treatment with antibiotics or local therapies was consistently effective.

Conclusions:

  • Cetuximab-induced acne is a common side effect of this EGFR inhibitor.
  • The acneiform eruptions differ from classical acne vulgaris.
  • Standard anti-acne treatments demonstrate effectiveness in managing cetuximab-induced acne.

Related Experiment Videos